Parvovirus B19 DNA, Quantitative, Real-Time PCR : 19724

PVPQT or 19724

Fifth Disease * Slapped Cheek Rash

1 mL (0.3 mL minimum) plasma collected in an EDTA (lavender-top) or
1 mL whole blood collected in an EDTA (lavender-top) or
1 mL amniotic fluid or amniotic fluid supernatant collected in a sterile leak-proof container or
1 mL serum collected in a red top tube (no gel) or Serum Separator Tube

Refrigerated.

Whole Blood: Room temperature: 48 hours; Refrigerated: 7 days; Frozen: Unacceptable
  
All other samples:  Room temperature: 48 hours; Refrigerated: 7 days; Frozen: 30 days

Sunday - Saturday

1 day

Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

Not Detected

Parvovirus B19 DNA, Quantitative, Real-Time PCR - Parvovirus B19 is the cause of an infection known as "Fifth Disease". This infection affects children primarily and causes a rash on the face, trunk, and limbs. Joint pain and swelling is more common in adults. Although a portion of those affected have only mild disease, patients with sickle cell anemia, or similar types of chronic anemia, can suffer from severe acute anemia. Infection during pregnancy can lead to severe complications for the fetus. Infections in immunocompromised patients may lead to serious complications including nephropathy, myocarditis, and persistent anemia. Although serologic detection of circulating antibodies (Parvovirus B-19 IgM & IgG) is useful to determine recent exposure to the virus, DNA testing provides the most reliable evidence of a persistent infection. Quantitative results of Parvovirus B19 viral load may be useful in determining the response to therapy (usually IVIG) and may be beneficial in assessing the risk for nosocomial transmission.